Free Trial
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

Amphastar Pharmaceuticals logo
$23.58 +0.24 (+1.03%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$24.04 +0.46 (+1.96%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Key Stats

Today's Range
$23.20
$23.72
50-Day Range
$22.96
$26.92
52-Week Range
$22.64
$53.96
Volume
465,368 shs
Average Volume
493,018 shs
Market Capitalization
$1.11 billion
P/E Ratio
8.54
Dividend Yield
N/A
Price Target
$32.33
Consensus Rating
Hold

Company Overview

Amphastar Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

AMPH MarketRank™: 

Amphastar Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 159th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amphastar Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amphastar Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Amphastar Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amphastar Pharmaceuticals are expected to decrease by -5.73% in the coming year, from $3.49 to $3.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amphastar Pharmaceuticals is 8.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amphastar Pharmaceuticals is 8.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.16.

  • Price to Earnings Growth Ratio

    Amphastar Pharmaceuticals has a PEG Ratio of 6.08. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amphastar Pharmaceuticals has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Amphastar Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.80% of the float of Amphastar Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in Amphastar Pharmaceuticals has recently decreased by 0.49%, indicating that investor sentiment is improving.
  • Dividend Yield

    Amphastar Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amphastar Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.80% of the float of Amphastar Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in Amphastar Pharmaceuticals has recently decreased by 0.49%, indicating that investor sentiment is improving.
  • News Sentiment

    Amphastar Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,875.00 in company stock.

  • Percentage Held by Insiders

    27.50% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amphastar Pharmaceuticals' insider trading history.
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock News Headlines

AMPH Amphastar Pharmaceuticals, Inc. - Seeking Alpha
Trump’s New Order Could Boost Social Security Benefits by 400%
If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Amphastar Pharmaceuticals Inc.DL-Exchang. Notes 2023(29) Bond
Amphastar Pharmaceuticals, Inc. (AMPH) - Yahoo Finance
See More Headlines

AMPH Stock Analysis - Frequently Asked Questions

Amphastar Pharmaceuticals' stock was trading at $37.13 at the start of the year. Since then, AMPH stock has decreased by 36.5% and is now trading at $23.58.
View the best growth stocks for 2025 here
.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Monday, November, 8th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.24 by $0.22. The company earned $112.20 million during the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a net margin of 19.38% and a trailing twelve-month return on equity of 22.20%.
Read the conference call transcript
.

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/08/2021
Today
7/02/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMPH
Employees
2,028
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.33
High Stock Price Target
$35.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+37.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
8.54
Forward P/E Ratio
6.76
P/E Growth
6.08
Net Income
$159.52 million
Pretax Margin
23.64%

Debt

Sales & Book Value

Annual Sales
$731.97 million
Cash Flow
$5.05 per share
Price / Cash Flow
4.67
Book Value
$15.23 per share
Price / Book
1.55

Miscellaneous

Free Float
34,176,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
0.72

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AMPH) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners